Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial.
Onoue T, Goto M, Wada E, Furukawa M, Okuji T, Okada N, Kobayashi T, Iwama S, Sugiyama M, Tsunekawa T, Takagi H, Hagiwara D, Ito Y, Morishita Y, Seino Y, Suga H, Banno R, Hamada Y, Ando M, Yamamori E, Arima H.
Onoue T, et al. Among authors: yamamori e.
PLoS One. 2020 Jan 28;15(1):e0228004. doi: 10.1371/journal.pone.0228004. eCollection 2020.
PLoS One. 2020.
PMID: 31990936
Free PMC article.
Clinical Trial.